FDA Brief

Warning letters Drugs

FDA warning letter to

Healthon Inc. dba Healthon

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.

What happened

In August 2025, FDA reviewed Healthon's website at healthon.com and found it offered compounded semaglutide and tirzepatide products. FDA said the site claimed these products had the 'same active ingredient' as Wegovy/Ozempic and Mounjaro/Zepbound, were 'clinically proven' for weight loss, and that the active ingredient was FDA-approved. FDA said compounded drugs are not FDA-approved and these claims are false or misleading, making the products misbranded.

What FDA found

  1. Healthon's website claimed its compounded semaglutide and tirzepatide had the same active ingredient as FDA-approved Wegovy/Ozempic and Mounjaro/Zepbound, which is false or misleading.

    FDCA § 502(a) [21 U.S.C. § 352(a)]; § 502(bb) [21 U.S.C. § 352(bb)]
  2. Healthon claimed its products were 'clinically proven' for weight loss, a misleading efficacy claim.

    FDCA § 502(a) [21 U.S.C. § 352(a)]; § 502(bb) [21 U.S.C. § 352(bb)]
  3. Healthon said the active ingredient in its formula is FDA-approved, implying the compounded product is FDA-approved when compounded drugs are not.

    FDCA § 502(a) [21 U.S.C. § 352(a)]; § 502(bb) [21 U.S.C. § 352(bb)]
  4. The misbranded products were introduced or delivered for introduction into interstate commerce.

    FDCA § 301(a) [21 U.S.C. § 331(a)]
  5. Receipt in interstate commerce of misbranded drugs, and delivery or proffered delivery, is prohibited.

    FDCA § 301(c) [21 U.S.C. § 331(c)]

What FDA wants

Within 15 working days, Healthon must send a written response to CDER's Office of Compounding Quality and Compliance describing steps taken to address the violations and prevent recurrence, with supporting documents. If it cannot complete the matter in that time, it must state the reason for delay and when it will do so.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compound pharmacies and their marketing partners
  • companies making 'same as' or 'FDA-approved' claims for compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low